ClinicalTrials.gg
CompletedNCT02436668Updated Dec 30, 2020Results posted

Study of Ibrutinib vs Placebo, in Combination With Nab-paclitaxel and Gemcitabine, in the First Line Treatment of Patients With Metastatic Pancreatic Adenocarcinoma (RESOLVE)

A Phase 3 interventional study of Ibrutinib and Gemcitabine in Metastatic Pancreatic Adenocarcinoma, sponsored by Pharmacyclics LLC.. Completed at 86 sites in 8 countries. Open to participants aged 18 Years and older. Per ClinicalTrials.gov, last updated 2020-12-30.

Sponsored by Pharmacyclics LLC. (part of AbbVie) · Phase 3, Interventional, and Treatment

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 3
Study type
Interventional
Enrollment
430
Allocation
Randomized
Ages
18 Years and older
Sex
All
01

Study summary

This is a phase 3 study to evaluate the efficacy of ibrutinib in combination with nab-paclitaxel and gemcitabine for the first line treatment of patients with metastatic pancreatic adenocarcinoma.

02

Conditions studied

  • Metastatic Pancreatic Adenocarcinoma
03

In context

Lead sponsor

Pharmacyclics LLC. is the lead sponsor of 54 studies on the registry; none are open to participants now.

Of its 10 completed or terminated interventional studies of FDA-regulated products, 9 (90%) have results posted.

First submitted before Pharmacyclics LLC. became part of AbbVie.

Counted across the registry records on this site, refreshed daily.

04

Who can participate

Ages eligible
18 Years and older
Sexes eligible
All
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  1. or cytologically confirmed diagnosis of pancreatic adenocarcinoma.
  2. Stage IV disease diagnosed within 6 weeks of randomization
  3. Adequate hematologic function:

    • (ANC) ≥1.5 x 109/L
    • count ≥100 x 109/L
    • ≥9 g/dL
  4. Adequate hepatic and renal function defined as:

    • and/or ALT ≤5.0 x (ULN) if liver , or ≤3 x ULN without liver metastases
    • Alkaline phosphatase \<3.0 x ULN or ≤5.0 x ULN if liver or bone metastases present
    • ≤1.5 x ULN (unless bilirubin rise is due to Gilbert's syndrome or of non-hepatic origin, such as hemolysis)
    • Estimated ≥30 mL/min
  5. \<1.5 x ULN and PTT (aPTT) \<1.5 x ULN
  6. ≥70.
  7. (ECOG) 0-1

Exclusion criteria

Exclusion Criteria:

  1. Prior therapies: BTK inhibitor, radiotherapy, radiotherapy in the setting, or cytotoxic chemotherapy for primary disease of pancreatic adenocarcinoma.
  2. Neuroendocrine (carcinoid, islet cell) or acinar pancreatic carcinoma
  3. Known brain or (CT or MRI scan of the brain required only in case of clinical suspicion of central nervous system involvement).
  4. Major surgery within 4 weeks of first dose of study drug.
  5. History of stroke or intracranial hemorrhage within 6 months prior to enrollment.
  6. Treatment with a strong cytochrome P450 (CYP) 3A inhibitor.
Terms in these criteria, in plain language(14)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Histologically or cytologically confirmed

The diagnosis was confirmed by looking at a sample under a microscope: tissue from a biopsy or surgery (histology), or cells from a fluid or needle sample (cytology).

Your pathology report is the document that shows this.

Absolute neutrophil count (ANC)

The number of neutrophils, white blood cells that help fight infection, in a given amount of blood. Too few raises the risk of infection.

It is a count, not a percentage of the white cells. Limits are written in units that mean the same: ≥ 1.5 × 10⁹/L is ≥ 1,500 per mm³ (µL). Each lab has its own reference range.

Platelets

Blood cells that help blood clot. Too few raises the risk of bleeding and bruising. A usual adult range is about 150–400 × 10⁹/L (150,000–400,000 per µL); each lab has its own reference range.

Hemoglobin (Hb)

The protein in red blood cells that carries oxygen. A low level is anemia, which can cause tiredness and breathlessness. Measured in g/dL or g/L (9 g/dL is 90 g/L).

ALT and AST (liver enzymes)

Two enzymes measured in a routine blood test of the liver. Higher levels can mean the liver is under strain or damaged. SGPT and SGOT are older names for ALT and AST.

Criteria usually give a limit as a multiple of the upper limit of normal (ULN), often higher when cancer has spread to the liver.

ULN (upper limit of normal)

The top of the normal range for a blood test, as set by the laboratory that runs it. Each lab prints its own range next to your result.

“≤ 2.5 × ULN” means the result can be up to two and a half times that top value.

Metastases

Cancer that has spread from where it began to other parts of the body. “Metastatic” cancer is cancer that has spread this way.

Bilirubin

A yellow substance made when red blood cells are broken down, which the liver clears. A high level can mean a problem with the liver or the bile ducts.

Criteria often allow more for people with Gilbert’s syndrome, a harmless inherited condition that raises bilirubin.

Creatinine clearance (CrCl)

How quickly the kidneys clear creatinine, a waste product, from the blood. A study may estimate it from a blood test with age, weight and sex (often by the Cockcroft–Gault formula), or measure it using blood and urine collected over a set time. Given in mL/min; higher is better.

INR, PT and aPTT (clotting tests)

Blood tests of how long blood takes to clot. The INR is the prothrombin time (PT) put on a common scale; about 1 is usual for someone not taking a blood thinner.

Criteria often make an exception for people on a blood thinner such as warfarin, whose INR is raised on purpose.

Karnofsky performance status (KPS)

A 0–100 scale of how well someone can carry out everyday activities. 100 is no complaints and no signs of illness; 70 is able to look after yourself but not to work or keep up normal activity; 50 is needing considerable help and frequent medical care.

Studies often ask for 60 or 70 and above. Your doctor gives the score.

ECOG performance status

A scale of how much an illness limits everyday activity. For people being assessed to join a study, scores run from 0 (fully active) to 4; lower is more active.

0
Fully active, no restrictions.
1
Limited in strenuous activity, but walking and able to do light work, such as housework or office work.
2
Walking and able to look after yourself, but unable to work; up and about more than half of waking hours.
3
Able to look after yourself only in part; in bed or a chair more than half of waking hours.
4
Unable to look after yourself at all; in bed or a chair all day.

Studies most often ask for 0–1 or 0–2. Your doctor gives the score; the WHO scale uses the same steps. The full scale also has 5, which records death.

Adjuvant and neoadjuvant

Neoadjuvant treatment is given before the main treatment (usually surgery), often to shrink a tumor. Adjuvant treatment is given after it, to lower the chance of the cancer coming back.

Leptomeningeal disease

Cancer that has spread to the leptomeninges, the thin layers covering the brain and spinal cord, and the fluid between them. It is not the same as brain metastases.

Criteria often treat it separately, and many studies leave it out even where treated brain metastases are allowed.

05

Study design

Phase
Phase 3
Primary purpose
Treatment
Allocation
Randomized
Intervention model
Parallel assignment
Masking
Double (Participant, Investigator)
Enrollment
430 participants (actual)

Study arms

  • Active comparator
    Ibrutinib

    Ibrutinib daily in combination with: Nab-paclitaxel and gemcitabine

    Drug: Ibrutinib · Drug: Gemcitabine · Drug: Nab-paclitaxel

  • Placebo comparator
    Placebo

    Placebo daily in combination with: Nab-paclitaxel and gemcitabine

    Drug: Gemcitabine · Drug: Nab-paclitaxel

Interventions

06

What researchers measure

Primary outcomes

  1. Progression Free Survival (PFS)

    PFS is defined as the time from the date of randomization until disease progression per RECIST 1.1 criteria assessed by investigator, or death from any cause, whichever occurs first.

    Time frame: Results at an overall median follow-up of 24.87 months

  2. Overall Survival (OS)

    OS, is defined as the time from date of randomization until date of death from any cause.

    Time frame: Results at an overall median follow-up of 24.87 months

Secondary outcomes

  1. Number of Participants With Adverse Events as a Measure of Safety and Tolerability of Ibrutinib and Nab-paclitaxel and Gemcitabine Versus Placebo in Combination With Nab-paclitaxel and Gemcitabine.

    This is a measure of percentage of subjects with Treatment Emergent Adverse Events Grade 3 or above collected Up to 30 days after the last participating subject discontinues study drug.

    Time frame: Results at an overall median follow-up of 24.87 months

  2. Overall Response Rate

    ORR is defined as the percentage of subjects who achieve a complete response or partial response, based on investigator assessment according to RECIST 1.1.

    Time frame: Results at an overall median follow-up of 24.87 months

  3. Clinical Benefit Response

    Subject achieved a ≥50% reduction in pain intensity (Memorial Pain Assessment Card \[MPAC\]) or analgesic consumption, or a 20-point or greater improvement in KPS for a period of at least 4 consecutive weeks, without showing any sustained worsening in other parameters. OR Subject was stable on all of the aforementioned parameters, and showed a marked, sustained weight gain (≥7% increase maintained for ≥4 weeks) not due to fluid accumulation (Burris 1997).

    Time frame: Results at an overall median follow-up of 24.87 months

  4. Carbohydrate Antigen 19-9 (CA19-9) Response

    The CA19-9 response rate is defined as the percentage of subjects with a decline of 20%, 90%, and other thresholds considered clinically meaningful, from baseline. This is a percentage of patients with \> or = 60% reduction from baseline.

    Time frame: Results at an overall median follow-up of 24.87 months

  5. Patient-reported Outcome (PRO) by European Organisation for Research and Treatment of Cancer (EORTC) Quality of Life Questionnaire Core 30 (QLQ-C30).

    Unit is the month: TUDD1 - the time between random \& 1st occurrence of a decrease in QLQ-C30 score ≥10 pts w/o improvement in QoL score of ≥10 points or any further QoL data due to deterioration. The proportion of subjects who met the "responder" criteria prior to subsequent anticancer therapy initiation. Response defined as achievement of a ≥50% reduction in MPAC visual analog scale which measures pain intensity or analgesic consumption, or a ≥20-point improvement from baseline in KPS sustained for a period of ≥ 4 consecutive weeks without showing any sustained worsening from baseline in any of the other parameters OR Subject stable on all parameters (pain and KPS), \& showed a marked, sustained weight gain (≥7% increase from baseline maintained for ≥4 weeks) not due to fluid accumulation.

    Time frame: Results at an overall median follow-up of 24.87 months

  6. Rate of Venous Thromboembolic Events (VTE)

    The VTE rate is defined as percentage of subjects with Venous thromboembolic events (SMQ) per investigator assessment.

    Time frame: Results at an overall median follow-up of 24.87 months

07

Results

Posted Nov 16, 2020

Participant flow

This study was conducted at 75 centers in the United States (US), European Union, and South Korea. The first subject enrolled 08 May 2015 and the last was enrolled on April 19, 2018.

Participant flow — Overall Study
MilestonePlacebo+Gemcitabine+Nab-PaclitaxelIbrutinib+Gemcitabine+Nab-paclitaxel
Started213211
Completed212207
Not completed14

Outcome measures

PrimaryProgression Free Survival (PFS)

PFS is defined as the time from the date of randomization until disease progression per RECIST 1.1 criteria assessed by investigator, or death from any cause, whichever occurs first.

Time frame:
Results at an overall median follow-up of 24.87 months
Reported as:
Median · Months
Progression Free Survival (PFS)
MonthsIbrutinib+Gemcitabine+Nab-paclitaxelPlacebo+Gemcitabine+Nab-Paclitaxel
Progression Free Survival (PFS)5.32 (3.75 to 5.49)6.01 (5.45 to 7.16)
Statistical analysis
  • Ibrutinib+Gemcitabine+Nab-paclitaxel vs Placebo+Gemcitabine+Nab-Paclitaxel · Log Rank · p = <0.0001 (P-value is from log-rank test stratified by the three randomization stratification factors \[KPS (70-80 vs. 90-100), liver metastasis (present vs. absent), and age (≤65 vs. \>65)\].) · Hazard ratio (hr): 1.525 · 95% CI 1.241 to 1.873
PrimaryOverall Survival (OS)

OS, is defined as the time from date of randomization until date of death from any cause.

Time frame:
Results at an overall median follow-up of 24.87 months
Reported as:
Median · Months
Overall Survival (OS)
MonthsIbrutinib+Gemcitabine+Nab-paclitaxelPlacebo+Gemcitabine+Nab-Paclitaxel
Overall Survival (OS)9.69 (8.57 to 10.41)10.78 (8.94 to 11.66)
Statistical analysis
  • Ibrutinib+Gemcitabine+Nab-paclitaxel vs Placebo+Gemcitabine+Nab-Paclitaxel · Log Rank · p = 0.3225 · Hazard ratio (hr): 1.109 · 95% CI 0.903 to 1.363
SecondaryNumber of Participants With Adverse Events as a Measure of Safety and Tolerability of Ibrutinib and Nab-paclitaxel and Gemcitabine Versus Placebo in Combination With Nab-paclitaxel and Gemcitabine.

This is a measure of percentage of subjects with Treatment Emergent Adverse Events Grade 3 or above collected Up to 30 days after the last participating subject discontinues study drug.

Time frame:
Results at an overall median follow-up of 24.87 months
Reported as:
Number · percentage of participants
Number of Participants With Adverse Events as a Measure of Safety and Tolerability of Ibrutinib and Nab-paclitaxel and Gemcitabine Versus Placebo in Combination With Nab-paclitaxel and Gemcitabine.
percentage of participantsPlacebo+Gemcitabine+Nab-PaclitaxelIbrutinib+Gemcitabine+Nab-paclitaxel
Subjects with any TEAE >= Grade 386.885.6
Subjects with ibrutinib/pbo-related TEAE >=Grade 355.754.3
SecondaryOverall Response Rate

ORR is defined as the percentage of subjects who achieve a complete response or partial response, based on investigator assessment according to RECIST 1.1.

Time frame:
Results at an overall median follow-up of 24.87 months
Reported as:
Number · percentage of Patients
Overall Response Rate
percentage of PatientsPlacebo+Gemcitabine+Nab-PaclitaxelIbrutinib+Gemcitabine+Nab-paclitaxel
Overall Response Rate42.3 (35.5 to 49.2)29.5 (23.3 to 36)
Statistical analysis
  • Placebo+Gemcitabine+Nab-Paclitaxel vs Ibrutinib+Gemcitabine+Nab-paclitaxel · Cochran-Mantel-Haenszel · p = 0.0058 · Risk ratio (rr): 0.695 · 95% CI 0.535 to 0.903
SecondaryClinical Benefit Response

Subject achieved a ≥50% reduction in pain intensity (Memorial Pain Assessment Card \[MPAC\]) or analgesic consumption, or a 20-point or greater improvement in KPS for a period of at least 4 consecutive weeks, without showing any sustained worsening in other parameters. OR Subject was stable on all of the aforementioned parameters, and showed a marked, sustained weight gain (≥7% increase maintained for ≥4 weeks) not due to fluid accumulation (Burris 1997).

Time frame:
Results at an overall median follow-up of 24.87 months
Reported as:
Number · percentage of patients
Clinical Benefit Response
percentage of patientsPlacebo+Gemcitabine+Nab-PaclitaxelIbrutinib+Gemcitabine+Nab-paclitaxel
Achieved a >=50% reduction in pain intensity25.827.5
>=20-pt improvement in KPS (>=4 consecutive weeks)1.40
Sustained weight gain (>=7% maintained >4 weeks11.75.7
SecondaryCarbohydrate Antigen 19-9 (CA19-9) Response

The CA19-9 response rate is defined as the percentage of subjects with a decline of 20%, 90%, and other thresholds considered clinically meaningful, from baseline. This is a percentage of patients with \> or = 60% reduction from baseline.

Time frame:
Results at an overall median follow-up of 24.87 months
Reported as:
Number · percentage of patients
Carbohydrate Antigen 19-9 (CA19-9) Response
percentage of patientsPlacebo+Gemcitabine+Nab-PaclitaxelIbrutinib+Gemcitabine+Nab-paclitaxel
Carbohydrate Antigen 19-9 (CA19-9) Response62.9 (56.0 to 69.4)53.6 (46.6 to 60.4)
Statistical analysis
  • Placebo+Gemcitabine+Nab-Paclitaxel vs Ibrutinib+Gemcitabine+Nab-paclitaxel · Cochran-Mantel-Haenszel · p = 0.0488 · Risk ratio (rr): 0.850 · 95% CI 0.722 to 1.0This 0.85 (0.722 to 1.0) with CI is referring to risk ratio not proportional/percentage of patients.
SecondaryPatient-reported Outcome (PRO) by European Organisation for Research and Treatment of Cancer (EORTC) Quality of Life Questionnaire Core 30 (QLQ-C30).

Unit is the month: TUDD1 - the time between random \& 1st occurrence of a decrease in QLQ-C30 score ≥10 pts w/o improvement in QoL score of ≥10 points or any further QoL data due to deterioration. The proportion of subjects who met the "responder" criteria prior to subsequent anticancer therapy initiation. Response defined as achievement of a ≥50% reduction in MPAC visual analog scale which measures pain intensity or analgesic consumption, or a ≥20-point improvement from baseline in KPS sustained for a period of ≥ 4 consecutive weeks without showing any sustained worsening from baseline in any of the other parameters OR Subject stable on all parameters (pain and KPS), \& showed a marked, sustained weight gain (≥7% increase from baseline maintained for ≥4 weeks) not due to fluid accumulation.

Time frame:
Results at an overall median follow-up of 24.87 months
Reported as:
Median · months
Patient-reported Outcome (PRO) by European Organisation for Research and Treatment of Cancer (EORTC) Quality of Life Questionnaire Core 30 (QLQ-C30).
monthsPlacebo+Gemcitabine+Nab-PaclitaxelIbrutinib+Gemcitabine+Nab-paclitaxel
Patient-reported Outcome (PRO) by European Organisation for Research and Treatment of Cancer (EORTC) Quality of Life Questionnaire Core 30 (QLQ-C30).6.14 (4.86 to 8.21)4.21 (2.86 to 5.82)
Statistical analysis
  • Placebo+Gemcitabine+Nab-Paclitaxel vs Ibrutinib+Gemcitabine+Nab-paclitaxel · Log Rank · p = 0.0782 (P-value is from log-rank test stratified by the three randomization stratification factors.) · Hazard ratio (hr): 1.265 · 95% CI 0.975 to 1.642
SecondaryRate of Venous Thromboembolic Events (VTE)

The VTE rate is defined as percentage of subjects with Venous thromboembolic events (SMQ) per investigator assessment.

Time frame:
Results at an overall median follow-up of 24.87 months
Reported as:
Number · Percentage of Participants
Rate of Venous Thromboembolic Events (VTE)
Percentage of ParticipantsPlacebo+Gemcitabine+Nab-PaclitaxelIbrutinib+Gemcitabine+Nab-paclitaxel
Rate of Venous Thromboembolic Events (VTE)10.8 (7.0 to 15.8)8.1 (4.8 to 12.6)
Statistical analysis
  • Placebo+Gemcitabine+Nab-Paclitaxel vs Ibrutinib+Gemcitabine+Nab-paclitaxel · Chi-squared · p = 0.3343

Adverse events

Collected over From first dose of study drug up to 30 days after the last dose of study drug. Non-serious events are listed at a 5% frequency threshold.

Adverse event summary by group
GroupDeathsSeriousOther
Placebo (Plus Nab-paclitaxel and Gemcitabine)188/212 (88.7%)127/212 (59.9%)211/212 (99.5%)
Ibrutinib (Plus Nab-paclitaxel and Gemcitabine)189/208 (90.9%)112/208 (53.8%)208/208 (100%)
Most frequent serious events
Showing 10 of 191
Most frequent serious events
EventPlacebo (Plus Nab-paclitaxel and Gemcitabine)Ibrutinib (Plus Nab-paclitaxel and Gemcitabine)
PyrexiaGeneral disorders17/21213/208
DiarrhoeaGastrointestinal disorders9/21214/208
PneumoniaInfections and infestations8/21213/208
Abdominal painGastrointestinal disorders11/2124/208
CholangitisHepatobiliary disorders4/2129/208
AnaemiaBlood and lymphatic system disorders9/2127/208
NauseaGastrointestinal disorders7/2123/208
AstheniaGeneral disorders7/2126/208
NeutropeniaBlood and lymphatic system disorders3/2126/208
Pancreatic carcinomaNeoplasms benign, malignant and unspecified (incl cysts and polyps)6/2126/208
Most frequent other events
Showing 10 of 60
Most frequent other events
EventPlacebo (Plus Nab-paclitaxel and Gemcitabine)Ibrutinib (Plus Nab-paclitaxel and Gemcitabine)
DiarrhoeaGastrointestinal disorders109/212147/208
NauseaGastrointestinal disorders107/212116/208
AstheniaGeneral disorders93/212100/208
AnaemiaBlood and lymphatic system disorders95/21290/208
AlopeciaSkin and subcutaneous tissue disorders87/21290/208
VomitingGastrointestinal disorders86/21285/208
PyrexiaGeneral disorders82/21285/208
Decreased appetiteMetabolism and nutrition disorders76/21285/208
NeutropeniaBlood and lymphatic system disorders84/21268/208
FatigueGeneral disorders65/21278/208

Baseline characteristics

Age, Categorical
Age, Categorical(Participants)Pbo+n-P/GIbr+n-P/GTotal
<=18 years000
Between 18 and 65 years119118237
>=65 years9493187
Age, Continuous
Age, Continuous(Years)Pbo+n-P/GIbr+n-P/GTotal
Median64.0 (32 to 85)64.0 (32 to 82)64.0 (32 to 85)
Sex: Female, Male
Sex: Female, Male(Participants)Pbo+n-P/GIbr+n-P/GTotal
Female9297189
Male121114235
Ethnicity (NIH/OMB)
Ethnicity (NIH/OMB)(Participants)Pbo+n-P/GIbr+n-P/GTotal
Hispanic or Latino11718
Not Hispanic or Latino197198395
Unknown or Not Reported5611
Race (NIH/OMB)
Race (NIH/OMB)(Participants)Pbo+n-P/GIbr+n-P/GTotal
American Indian or Alaska Native000
Asian5953112
Native Hawaiian or Other Pacific Islander000
Black or African American7512
White142146288
More than one race011
Unknown or Not Reported5611
08

Study locations

86 sites
  • Oncology Specialties, PC; Clearview Cancer Institute
    Huntsville, Alabama 35805, United States
  • Arizona Center for Cancer Care
    Avondale, Arizona 85323, United States
  • St. Mary's Medical Center
    Daly City, California 94015, United States
  • Moores UCSD Cancer Center
    La Jolla, California 92093, United States
  • Cedars Sinai Medical Center
    Los Angeles, California 90048, United States
  • Norwalk Hospital
    Norwalk, Connecticut 06856, United States
  • Eastern Connecticut Hematology/Oncology Assoc.
    Norwich, Connecticut 06360, United States
  • Bethesda Memorial Hospital
    Boynton Beach, Florida 33425, United States
  • Florida Hospital Tampa
    Tampa, Florida 33613, United States
  • University Cancer & Blood Center, LLC
    Athens, Georgia 30607, United States
  • Northwest Georgia Oncology Centers, PC
    Marietta, Georgia 30060, United States
  • Ingalls Memorial Hospital Cancer Research Center
    Harvey, Illinois 64026, United States
  • Joliet Oncology-Hematology Associates, LTD
    Joliet, Illinois 60435, United States
  • Investigative Clinical Research of Indiana
    Indianapolis, Indiana 46260, United States
  • Mary Bird Perkins Cancer Center
    Baton Rouge, Louisiana 70809, United States
  • Our Lady of the Lake Physician Group
    Baton Rouge, Louisiana 70809, United States
  • Center for Cancer and Blood Disorders
    Bethesda, Maryland 20817, United States
  • Berkshire Hematology Oncology Services at Berkshire Medical Center Cancer and Infusion Center
    Pittsfield, Massachusetts 01201, United States
  • Saint Joseph Mercy Health System
    Chelsea, Michigan 48118, United States
  • Sparrow Regional Cancer Center
    Lansing, Michigan 48912, United States
  • Nebraska Medicine - Peggy D. Cowdery Patient Care Center
    Omaha, Nebraska 68198, United States
  • The Presbyterian Hospital
    Charlotte, North Carolina 28204, United States
  • University of Cincinnati Medical Center
    Cincinnati, Ohio 45267, United States
  • Penn State University Milton S. Hershey Medical Center
    Hershey, Pennsylvania 17033, United States
  • Gibbs Cancer Center
    Spartanburg, South Carolina 29303, United States
  • Scott & White Memorial Hospital
    Temple, Texas 76508, United States
  • MultiCare Health System Institute for Research and Innovation
    Tacoma, Washington 98405, United States
  • Wenatchee Valley Hospital & Clinics
    Wenatchee, Washington 98801, United States
  • ULB Hôpital Erasme
    Bruxelles, 1070, Belgium
  • Cliniques Universitaires Saint-Luc
    Bruxelles, 1200, Belgium
  • Grand Hôpital de Charleroi
    Gilly, 6060, Belgium
  • UZ Leuven
    Leuven, 3000, Belgium
  • C. H. U. Sart Tilman
    Liège, 4000, Belgium
  • Centre Antoine Lacassagne
    Nice cedex 02, Alpes Maritimes 06189, France
  • Centre Paul Strauss
    Strasbourg cedex, Bas Rhin 67091, France
  • Hôpital de la Timone
    Marseille cedex 5, Bouches-du-Rhône 13385, France
  • Centre Georges François Leclerc
    Dijon cedex, Côte-d'Or 21079, France
  • CHU Besançon - Hôpital Jean Minjoz
    Besançon, Doubs 25030, France
  • Groupe Hospitalier Saint André - Hôpital Saint André
    Bordeaux, Gironde 33000, France
  • CHU de Toulouse - Hôpital Rangueil
    Toulouse Cedex 9, Haute Garonne 31059, France
  • Hôpital Nord Franche Comté
    Doubs, Montbeliard 25209, France
  • Hôpital Saint-Antoine
    Paris cedex 12, Paris 75571, France
  • CHU Poitiers - Hôpital la Milétrie
    Poitiers Cedex, Vienne 86021, France
  • Groupe Hospitalier Pitie-Salpetriere
    Paris, 75013, France
  • Universitaetsklinikum Tuebingen
    Tuebingen, Baden Wuerttemberg 72076, Germany
  • Universitaetsklinikum Ulm
    Ulm, Baden Wuerttemberg 89070, Germany
  • Klinikum der Johann Wolfgang Goethe-Universitaet
    Frankfurt, Hessen 60590, Germany
  • Universitaetsklinikum Koeln
    Koeln, Nordrhein Westfalen 50937, Germany
  • Gemeinschaftspraxis Haematologie und Onkologie
    Dresden, Sachsen Anhalt 01307, Germany
  • Universitaetsklinikum Leipzig AoeR
    Leipzig, Sachsen 04103, Germany
  • Onkologische Schwerpunktpraxis Kurfuerstendamm
    Berlin, 10707, Germany
  • Azienda Ospedaliero Universitaria Ospedali Riuniti
    Ancona, Italy
  • Azienda Ospedaliero Universitaria San Martino
    Genova, 16132, Italy
  • Ospedale San Raffaele
    Milano, 20132, Italy
  • IEO Istituto Europeo di Oncologia
    Milano, 20141, Italy
  • Azienda Ospedaliera Ospedale Niguarda Ca' Granda
    Milano, 20162, Italy
  • Istituto Nazionale Tumori Fondazione G. Pascale
    Napoli, 80131, Italy
  • IOV - Istituto Oncologico Veneto IRCCS
    Padova, 35128, Italy
  • Fondazione IRCCS Policlinico San Matteo
    Pavia, 27100, Italy
  • Azienda Ospedaliero Universitaria Pisana
    Pisa, 56126, Italy
  • IRCCS Ospedale Casa Sollievo della Sofferenza
    San Giovanni Rotondo, 71013, Italy
  • Seoul National University Bundang Hospital
    Seongnam-si, Gyeonggi-do 13620, Korea, Republic of
  • Chonnam National University Hwasun Hospital
    Hwasun, Jeollanam-do 58128, Korea, Republic of
  • Seoul National University Hospital
    Seoul, 03080, Korea, Republic of
  • Yonsei University Health System
    Seoul, 03722, Korea, Republic of
  • Asan Medical Center
    Seoul, 05505, Korea, Republic of
  • Samsung Medical Center
    Seoul, 06351, Korea, Republic of
  • The Catholic University of Korea, Seoul St. Mary's Hospital
    Seoul, 06591, Korea, Republic of
  • Korea University Guro Hospital
    Seoul, 152-703, Korea, Republic of
  • ICO l´Hospitalet - Hospital Duran i Reynals
    L'Hospitalet de Llobregat, Barcelona 08908, Spain
  • Hospital del Mar
    Barcelona, 08003, Spain
  • Specialist
    Barcelona, 08006, Spain
  • Hospital Universitari Vall d'Hebron
    Barcelona, 08035, Spain
  • Hospital Clinic i Provincial de Barcelona
    Barcelona, 08036, Spain
  • Hospital Universitario 12 de Octubre
    Madrid, 28041, Spain
  • Hospital Universitario La Paz
    Madrid, 28046, Spain
  • Hospital Clinico Universitario Virgen de la Victoria
    Málaga, 29010, Spain
  • Hospital Universitario Virgen Macarena
    Sevilla, 41009, Spain
  • Hospital Universitario Virgen del Rocio
    Sevilla, 41013, Spain
  • Derriford Hospital
    Plymouth, Devon PL6 8BQ, United Kingdom
  • Broomfield Hospital
    Chelmsford, Essex CM1 7ET, United Kingdom
  • The Christie
    Manchester, Greater Manchester M20 4BX, United Kingdom
  • Southampton General Hospital
    Southampton, Hampshire SO16 6YD, United Kingdom
  • The Clatterbridge Cancer Centre
    Liverpool, Merseyside L7 8XP, United Kingdom
  • Royal Marsden Hospital
    Sutton, Surrey SM2 5PT, United Kingdom
  • Royal Free Hospital
    London, NW3 2QG, United Kingdom
09

References and documents

Study documents

PDFs hosted by the registry, ClinicalTrials.gov.

10

Timeline

Tracking since Sep 25, 2026
Not marked actual or estimatedDates not marked actual or estimated

The record gives a start of May 2015, a primary completion of Oct 2018 and a completion of Apr 2019. It does not say whether these dates are actual or estimated.

Results were first posted in Nov 2020, 2 years 1 month after primary completion.

How these figures are worked out, and which studies are left out of them.

Registered
May 4, 2015
First posted
May 7, 2015
Start
May 2015
Primary completionActual
Oct 2018
CompletionActual
Apr 25, 2019
Results first posted
Nov 16, 2020
Last update
Dec 30, 2020
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Dec 30, 2020, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
11

Registry details

Key details

Study ID
NCT02436668
Lead sponsor
Pharmacyclics LLC.
Responsible party
Sponsor
First posted
May 7, 2015
Start date
May 2015
Primary completion
Oct 2018
Completion
Apr 25, 2019
Results posted
Nov 16, 2020
Last update
Dec 30, 2020

Study contacts

George Cole, MD
study director · Pharmacyclics LLC.

Oversight

Data monitoring committee
Yes
FDA-regulated drug
Yes
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is completed, as verified in Dec 2020. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drug tested here: Ibrutinib

Start the discussion